Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744826 | 1.00 | PPARD (0.55) | PPARDPPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL1744825 | 1.00 | PPARD (0.55) | PPARDPPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL16552765 | 0.99 | PPARD (0.54) | PPARDPPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL16552764 | 0.99 | PPARD (0.54) | PPARDPPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL16552762 | 0.99 | PPARD (0.54) | PPARDPPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL1244040 | 0.96 | PPARD (0.58) | PPARDPPARGPPARAKDM4EALDH1A1 | |
| SCHEMBL1744318 | 0.94 | PPARD (0.56) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1744320 | 0.94 | PPARD (0.56) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1744573 | 0.94 | PPARD (0.56) | PPARDPPARGPPARAAPEX1 | |
| SCHEMBL1744315 | 0.94 | PPARD (0.56) | PPARDPPARGPPARAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360139-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | VTV THERAPEUTICS LLC (US) | 2025-11-27 | — | — | US | claimed |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | claimed |
| EP-4031124-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | Reneo Pharmaceuticals, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| CN-114727976-A | Use of PPAR-delta agonists in the treatment of renal disease | 雷内奥制药公司 | 2022-07-08 | — | — | CN | claimed |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | RENEO PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | claimed |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | claimed |
| CN-113747891-A | Use of PPAR delta agonists in the treatment of Fatty Acid Oxidation Disorders (FAOD) | 雷内奥制药公司 | 2021-12-03 | — | — | CN | claimed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | claimed |
| EP-3756661-A1 | USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY | vTv Therapeutics LLC (US) | 2020-12-30 | — | — | EP | claimed |
| US-20180296562-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | TRANSTECH PHARMA, LLC | 2018-10-18 | — | — | US | claimed |
| US-20150072985-A1 | USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY | VTVX HOLDINGS I LLC | 2015-03-12 | — | — | US | claimed |
| EP-1979311-B1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-06-13 | — | — | EP | claimed |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | claimed |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | VTVX HOLDINGS II LLC | 2009-04-09 | — | — | US | claimed |
| EP-1979311-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | claimed |
| US-20250360139-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | VTV THERAPEUTICS LLC (US) | 2025-11-27 | — | — | US | disclosed |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | RENEO PHARMACEUTICALS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-1979311-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072985-A1 | USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY | PPARA, PPARD, PPARG | PPARD 2/4885PPARG 3/4885PPARA 1/4885 |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | PPARG, PPARD, PPARA | PPARD 2/4885PPARG 1/4885PPARA 3/4885 |
| US-20090093484-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | PPARD 2/4885PPARG 1/4885PPARA 3/4885 |
| US-20180296562-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | PPARA, PPARG, PPARD | PPARD 3/4885PPARG 2/4885PPARA 1/4885 |
| US-20250360139-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | PPARA, PPARG, PPARD | PPARD 3/4885PPARG 2/4885PPARA 1/4885 |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | PPARD, PPARA, MTPN | PPARD 1/4885PPARG 4/4885PPARA 2/4885 |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | PPARD, ACOX1, CPT1A | PPARD 1/4885PPARG 4/4885PPARA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.